Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 767.96

+2.6%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (1656)	10/16/2014 1:37:36 AM
From: Miljenko Zuanic	of 3559

Great late-stage pipeline (ready to file candidates), ended , however … <and am eager to see the initial results for the CD20 plus CD3 bispecific antibody and for the anti-PDGF mAB/Eylea combination> RE: anti-PDGF/VEGF combination (PI), from planed 24 pts (6 per regimen), they are down to ONLY 12? Can you do appropriate safety PI based on 3 pts per dose? REGN didn’t have any “explanation” on this, when I asked. Old ways, public disclosure secrecy, going on and on…can not go back into any stocks, even “when and if” I see god opportunity!!!??? RE: ESPN(potential future competitors), after “SUCKER” draw price to 30 level, and shorted before “expected” secondary at 20…well, you know (or guess) what I mean…

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next